How much esprit is in ESPRIT?

Stroke

Volumn 37, Issue 11, 2006, Pages 2856-2857

  Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; TICLOPIDINE;

ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG WITHDRAWAL; HEADACHE; HUMAN; INDUSTRIALIZATION; LIFE EXPECTANCY; LOW DRUG DOSE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME; CEREBROVASCULAR ACCIDENT; DRUG COMBINATION; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ASPIRIN; CEREBROVASCULAR ACCIDENT; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 33750942726     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000244754.18106.85     Document Type: Article

References (19)

1. Wolfe CD. The impact of stroke. Br Med Bull. 2000;56:275-286.
2. Leys D, Kwiecinski H, Bogousslavsky J, Bath P, Brainin M, Diener H, Kaste M, Sivenius J, Hennerici M, Hacke W. Prevention. Cerebrovasc Dis. 2004;17(suppl 2):15-29.
3. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
4. Diener H, Bogousslavsky J, Brass L, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H-J; on behalf of the MATCH Investigators. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: the MATCH trial results. Lancet. 2004;364:331-334.
5. Diener HC, Cuhna L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
6. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-1673.
7. Bousser MG, Eschwege E, Haguenau M, Lefaucconier JM, Thibult N, Touboul D, Touboul PJ. AICLA: controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke. 1983;13:5-14.
8. Acheson J, Danta G, Hutchinson EC. Controlled trial of dipyridamole in cerebral vascular disease. Br Med J. 1969;1:614-615.
9. American-Canadian Co-operative Study Group. Persantin-aspirin in cerebral ischemia, part II: end point results. Stroke. 1985;16:406-415.
10. Diener HC, Forbes C, Riekkinen PJ, Sivenius J, Smets P, Lowenthal A, and the ESPS Group. European Stroke Prevention Study 2: efficacy and safety data. J Neurol Sci. 1997;151(Suppl):S1-S77.
11. De Schreyver E, on behalf of the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. Design of ESPRIT: an international randomised trial for secondary prevention of non-disabling cerebral ischaemia of arterial origin. Cerebrovasc Dis. 2000;10:147-150.
12. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999;65:255.
13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;524:71-86.
14. The ESPS Group. The European Stroke Prevention Study (ESPS): principal end-points. Lancet. 1987;2:1351-1354.
15. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
16. Albers G, Diener H-C, Frison L, Grind M, Nevinson M, Partridge S, Halperin J, Horrow J, Olsson S, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA. 2005;293:690-698.
17. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698.
18. Keltz TN, Innerfield M, Gitler B, Cooper JA. Dipyridamole-induced myocardial ischemia. JAMA. 1987;257:1515-1516.
19. Hankey GJ. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care. Cerebrovasc Dis. 2004;17(suppl 3):11-16.